Ovum, a Melbourne women's health startup, raised an A$4m (about $2.8m) seed round announced on 23 June 2026. Admiralty Capital Group led. Antler, Giant Leap, Aviron Investments, Foggy Valley Aotearoa, Brisbane Angels and Think & Grow took part, and LaunchVic increased its backing through its Alice Anderson Fund.
IT Brief Australia reported that the valuation has tripled since the pre-seed round about a year earlier, but did not give a figure. The company said the funding will go toward growing its team and expanding its longitudinal women's health dataset.
“I've sat on both sides of the desk, as a patient and as a doctor, and that's why this mission matters so much to me.”Dr Ariella Heffernan-Marks, Founder, Ovum
What Ovum does
Ovum was founded by Dr Ariella Heffernan-Marks, a medical doctor. Its app is an AI-based health journal that brings together symptoms, lifestyle data, biometrics, reproductive health records, medications, appointments and medical reports into a single record. From that record it produces health summaries and questions for appointments.
It also offers a Pay It Forward model that lets users gift memberships to others. The app launched in August 2025. IT Brief Australia reports more than 20,000 downloads, more than 60,000 women's health data insights captured and more than 113,000 AI health conversations. Users range in age from 15 to 84, and 83% have opted in to share anonymised data for research. Women's Agenda reports growth of 30% a month.
Ovum has not disclosed a headcount.
Partners and research
Medibank signed with the company before launch, according to IT Brief Australia. Other partners include Fernwood Fitness, Sweat and Menopause Friendly Australia, and Ovum is running a pilot with the Australian Red Cross Lifeblood.
Clinical trials began earlier in 2026 with St George Hospital and the Royal Hospital for Women. Women's Agenda describes them as reportedly the first in Australia to assess AI as a preventative health tool designed for women. Shared data is encrypted and held to GDPR and SOC 2 Type II standards, the company says.
What the founder and investors said
Heffernan-Marks said: "I've sat on both sides of the desk, as a patient and as a doctor, and that's why this mission matters so much to me."
Amanda Andriano, founding partner at Admiralty Capital Group, was quoted by Women's Agenda saying that Ovum "combines mission, market timing and technical capability with an exceptional founder".
Women's Agenda also quoted Heffernan-Marks saying, "Ovum exists to help women better understand their bodies", and described Ovum as building what it calls the first AI infrastructure for women's health. The company did not give a headcount.
The funding so far
Ovum's earlier funding was an A$1.7m pre-seed round raised about a year before this one, according to IT Brief Australia and Women's Agenda. The seed more than doubles that amount, and the company says its valuation tripled.
The seed is small in dollar terms, but the company has a user base, an enterprise partner in Medibank and clinical studies under way. What remains to be shown is whether the dataset, which the company describes as longitudinal and consented, can be turned into revenue beyond membership fees.